New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
13:25 EDTBMRN, BMRN, BMRN, CLVS, CLVS, CLVS, TSRO, TSRO, TSROLeerink's biotech analysts hold an analyst/industry conference call
Biotech Analysts Kozul, Liang and Schwartz provide a review of development programs for novel oral PARPs (Poly(ADP-ribose) polymerase); Biomarin's BMN-673, Clovis Oncology's Rucaparin and Tesaro's Niraparib on an Analyst/Industry conference call to be held on February 4 at 2 pm.
News For BMRN;CLVS;TSRO From The Last 14 Days
Check below for free stories on BMRN;CLVS;TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:02 EDTBMRNCatalyst Pharmaceutical, BioMarin in amended license agreement
Catalyst Pharmaceutical (CPRX) disclosed in a regulatory filing that on April 15, effective as of April 8, the company and BioMarin Pharmaceutical (BMRN) entered into Amendment No. 1 to License Agreement, amending in certain respects the License Agreement, dated October 26, 2012, between the company and BioMarin. The company intends to submit a FOIA Confidential Treatment Request to the SEC pursuant to Rule 24b-2 under the SEC Act of 1934, as amended, requesting that it be permitted to redact certain portions of the Amendment. The omitted material will be included in the request for confidential treatment.
April 15, 2014
11:01 EDTCLVSClovis volatility increases on wide price movement
Subscribe for More Information
April 14, 2014
08:22 EDTBMRNBioMarin says FDA extends Kuvan market exclusivity by six months
Subscribe for More Information
April 10, 2014
10:24 EDTCLVSClovis volatility elevated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use